Below are Rx IP Update’s most-read articles of 2021 (see also our 2021 Highlights in Canadian Life Sciences IP and Regulatory Law):
- Federal Court remits BELSOMRA CSP timing refusal for redetermination
- Update on biosimilars in Canada – October 2021
- Health Canada paving the way for more AI/ML medical devices
- First year of Project Orbis leads to 38 approvals of cancer therapies, including 8 by Health Canada
- Patentability of diagnostic methods – has the Canadian Patent Office drawn the line?
- New CADTH Report on Health Technology Trends in 2021
- FCA upholds reconsideration decision maintaining $100M+ award against Apotex for cefaclor patent infringement
- Federal Court decision regarding glatiramer acetate finds one patent obvious and another valid and infringed
- Supreme Court of Canada denies Amgen leave to appeal decision invalidating its filgrastim patent
- Federal Court of Appeal upholds decision finding Seedlings' LifeCard patent invalid and not infringed by Pfizer’s EpiPen
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group or the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB releases proposed amendment to Interim Guidance for comment
On June 20, 2023, the Patented Medicine Prices Review Board released a proposal to amend the Interim Guidance, which sets out the approach for reviewing the prices of patented medicines under the July...Read More -
2023 Mid-Year Highlights in Canadian Life Sciences IP and Regulatory Law
In the first half of 2023, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More -
Health Canada publishes guidance on distinction between advertising and other activities for health products
Promotional messages and activities regarding a health product are subject to the advertising provisions under the Food and Drugs Act (FDA), the Controlled Drugs and Substances Act and/or their associ...Read More